Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 185.97

-0.4%

Feb 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (7308)	9/23/1997 5:07:00 PM
From: squetch	of 32384

Henry, Paxene is IVAX/NPRO version of paclitaxel. I don't understand the Orphan Drug Act. Below is the "clearest" wording of this status. "Once an orphan drug is approved,exclusivity gives sponsors legal protection against introduction of an identical competing product for seven years." What is meaning of "identical competing product"? That says generic to me. Paxene really a generic form of paclitaxel. So the act protects against generics? fda.gov Stan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next